Skip to main content
Equibles
EXOZ logo

EXOZ · Exozymes Inc. · Metrics

Track EXOZ — free

Use EXOZ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EXOZ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.77 +0.01 (+0.17%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Given the Company's current operating cash burn, its existing working capital as of June 30, 2026, is not sufficient to fund operations for twelve months from the date these condensed unaudited consolidated financial statements are issued, and management has concluded that substantial doubt exists about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$57.96M
Shares
9.28M
Volume · Oct 2 2116 Avg daily vol (3M) 7313

EXOZ metrics

53 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.77
Market cap
$57.96M

Price action

20 metrics
Price change (1W)
-7.6%
Price change (30D)
-15.8%
Price change (3M)
-32.0%
Price change (6M)
-34.0%
Price change (YTD)
-47.1%
Price change (1Y)
-56.6%
Trailing year
Price change (5Y)
—
52-week high
$16.50
52-week low
$4.40
Change from 52-week high
-65.0%
Change from 52-week low
+31.1%
Annualized volatility
78.1%
Annualized volatility (3M)
81.6%
Beta
1.1
RSI (14D)
39.9
Price vs SMA 50
-4.2%
Price vs SMA 200
-32.1%
Avg volume (3M)
7,313
Relative volume
0.3
Average dollar volume
$45,006

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
9.28M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
15.9
reciprocal yield 6.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-17.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-2,563.5%
Trailing 12 months
Net margin
-2,909.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$10.56M
Net income (TTM)
−$10.19M
Trailing 12 months
Diluted EPS (TTM)
$-1.20
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.40

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-278.9%
Return on assets
-127.7%
Debt / equity
—
Current ratio
3.8
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
3.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$5.65M
Latest balance sheet
Cash & equivalents
$5.65M
Total assets
$7.98M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$7.00M
Capital expenditures (TTM)
$145,901
R&D (TTM)
$4.89M
SG&A (TTM)
—
Stock compensation (TTM)
$2.82M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
9
13F filer change QoQ
+2
Institutional ownership
1.3%

Short interest

3 metrics
Short interest
0.2%
Latest settlement · 3.1 days to cover
Days to cover
3.1d
Short-squeeze score
44 / 100

Insider activity

2 metrics
Net insider buying (90D)
$6,405
Insider-sentiment score
74 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 2010788 CUSIP 461874109 Visit website Investor relations